{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-035656","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2024-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.687119+00:00","generated_at":"2026-06-04T08:28:11.255837+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Axsome CRESCENDO survey: 77% of treated NT1 patients still have cataplexy; 74% cognitive impairment","bullets":["77% of treated NT1 patients continue to experience cataplexy attacks despite current therapy.","64% have excessive daytime sleepiness (ESS>10); 74% exhibit cognitive impairment (BC-CCI≥5).","Depression and anxiety reported by 45% and 57% of patients, respectively.","Survey included 203 adults; top treatments were wake-promoting agents (53%), oxybates (47%), stimulants (42%).","Axsome plans to present detailed CRESCENDO results at upcoming scientific meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-035656","json":"https://secwatch.observer/filing/0000950170-24-035656.json","markdown":"https://secwatch.observer/filing/0000950170-24-035656.md","text":"https://secwatch.observer/filing/0000950170-24-035656.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024035656/0000950170-24-035656-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000095017024035656/axsm-20240325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T08:28:11.255837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}